Abstract

Background: Lifelong oral anticoagulant (OAC) use is associated with higher intracranial hemorrhage (ICH) risk in nonvalvular atrial fibrillation (NVAF) patients. We aimed to assess the long-term outcomes of left atrial appendage closure (LAAC) in NVAF patients at high baseline ICH risk, as LAAC was FDA-approved for NVAF patients who have a reasonable rationale to seek a nonpharmacological alternative to lifelong OAC use. Methods: We collected baseline and follow up data from consecutive NVAF patients who had LAAC because of either past ICH or finding cerebral microbleeds (CMB) on MRI without ICH (CMB-only). The outcome measures were the occurrence of ICH or acute ischemic stroke (AIS) after LAAC. Results: Out of a total of 644 LAAC performed in a single hospital system between 2015-2022, 142 NVAF patients had LAAC with WATCHMAN because of past ICH or CMB-only. Their mean age was 75.8± 7.6, 41 were female (29%). Mean CHA 2 DS 2 -VASc score was 5.24±1.4. Of the 142 patients, 67 (47.2%) had intraparenchymal hemorrhage (IPH, 52% related to cerebral amyloid angiopathy [CAA]), 19 (13.4%) had non-traumatic subdural hemorrhage (SDH), 36 (25.3%) had traumatic ICH (T-ICH), and 20 (14.08%) were CMB-only (65% with CAA pattern). Eighty-one patients were discharged on OAC (57%) and 133 patients were not taking OAC at 1 year (94%). Over a mean 1.98 years follow up, one patient had recurrent non-traumatic IPH (incidence rate [IR] 0.36 per 100 patient-years), four had traumatic ICH/SDH due to severe falls (IR 1.4%/year), and five had AIS (IR 1.78%/year). Conclusions: In NVAF patients at high ICH risk, our results show a 74% decrease in AIS risk (actual 1.76%/year vs expected 6.8%/year based on CHA 2 DS 2 -VASc). Despite the very high ICH risk population studied including at least 48 CAA patients, only one patient had a recurrent IPH after LAAC. LAAC should be considered in NVAF patients at high ICH risk and studied in RCTs in this cohort.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call